Correlation Between Viatris and Carmell Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viatris and Carmell Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viatris and Carmell Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viatris and Carmell Therapeutics, you can compare the effects of market volatilities on Viatris and Carmell Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viatris with a short position of Carmell Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viatris and Carmell Therapeutics.

Diversification Opportunities for Viatris and Carmell Therapeutics

-0.52
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Viatris and Carmell is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Viatris and Carmell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Carmell Therapeutics and Viatris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viatris are associated (or correlated) with Carmell Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Carmell Therapeutics has no effect on the direction of Viatris i.e., Viatris and Carmell Therapeutics go up and down completely randomly.

Pair Corralation between Viatris and Carmell Therapeutics

Given the investment horizon of 90 days Viatris is expected to generate 0.18 times more return on investment than Carmell Therapeutics. However, Viatris is 5.59 times less risky than Carmell Therapeutics. It trades about 0.1 of its potential returns per unit of risk. Carmell Therapeutics is currently generating about -0.1 per unit of risk. If you would invest  1,042  in Viatris on September 2, 2024 and sell it today you would earn a total of  267.00  from holding Viatris or generate 25.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Viatris  vs.  Carmell Therapeutics

 Performance 
       Timeline  
Viatris 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Viatris are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Viatris may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Carmell Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Carmell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Carmell Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Viatris and Carmell Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viatris and Carmell Therapeutics

The main advantage of trading using opposite Viatris and Carmell Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viatris position performs unexpectedly, Carmell Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Carmell Therapeutics will offset losses from the drop in Carmell Therapeutics' long position.
The idea behind Viatris and Carmell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas